title: Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
abstract: The therapeutic efficacy and side effects of alpha-2c-interferon (IFN-alpha 2c) treatment of hairy cell leukemia were compared between two different dose regimen: 10 patients received maximum tolerable doses of IFN-alpha 2c for 1 year (group A), and 11 patients received minimum doses of IFN-alpha 2c, which induced an optimal biological response (group B). Induction of neopterin excretion was chosen as the marker to define biological response and the dose of IFN-alpha 2c applied was on average only one tenth of that in group A cases. Average time of treatment in group B was 42 weeks. The data indicate that both dose levels are effective in the treatment of advanced hairy cell leukemia but that the low dose regimen is free of toxicity. Laboratory investigations on the mechanism of IFN-mediated remission in HCL further revealed that hairy cells are resistant to lysis by IFN-alpha activated large granular lymphocytes and that improved natural killer function subsequent to IFN-alpha treatment in vivo is primarily due to the disappearance of leukemic hairy cells which dilute the natural killer effector cells. These findings support the view of a direct antitumor activity of IFN-alpha as the main therapeutic principle.
authors: Department of Internal Medicine, University of Innsbruck, Austria.
authors: C
authors: C
authors: Huber
authors: W
authors: W
authors: Aulitzky
authors: H
authors: H
authors: Tilg
authors: I
authors: I
authors: von Lüttichau
authors: J
authors: J
authors: Troppmair
authors: K
authors: K
authors: Nachbauer
authors: G
authors: G
authors: Gastl
mesh_terms: D000328:Adult; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D007943:Leukemia, Hairy Cell / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged
chemical_list: D007370:Interferon Type I